Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-42 in Vestibular Schwannoma and Meningioma
NCT02282917Phase 1Terminated
- Sponsor
- Massachusetts Eye and Ear
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AR-42 in vestibular schwannoma (VS) and meningioma, sponsored by Massachusetts Eye and Ear. Primary endpoints: Ratio of Phospho-AKT (p-AKT) to AKT at 3 weeks and Peripheral Phospho-AKT (p-AKT) to AKT Ratio at 3 weeks. Started Dec 2015; status: terminated.
02
Drugs
AR-42
03
Conditions
vestibular schwannoma (VS)meningioma
Beyond the preview
Go deeper on NCT02282917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282917.